Clinical validation of controlled exposure to cat dander in the Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU)

Hossenbaccus, L., Linton, S., Garvey, S. et al. Allergy Asthma Clin Immunol 21, 33 (2025). https://doi.org/10.1186/s13223-025-00978-z

Abstract

Background

Cat allergen is the second most common cause of perennial allergic rhinitis. Despite its prevalence (~ 20% of the population), many patients continue to suffer from persistent symptoms due to constant exposure to cat allergens that reduce treatment efficacy. Modelling of the disease can improve our understanding of its onset and progression. The Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU) is a controlled allergen challenge facility that has recently undergone a successful technical validation for cat dander exposure, measuring Felis domesticus 1 (Fel d 1). We then sought to perform a clinical validation with cat-allergic and non-allergic participants.

Methods

This study consisted of 3 visits. Recruited participants attended a Screening visit where eligibility was assessed, and a skin prick test (SPT) was completed. Successfully screened cat-allergic and non-allergic participants were invited back for the Allergen Exposure visit. They attended one of two 3-hour cat dander exposure Sessions in the SPaC-EEU, due to space limitations, with a target Fel d 1 concentration of 70 ng/m3. Fel d 1 concentrations were collected using air sampling cassettes and processed using a Fel d 1-specific ELISA. Real-time particle counts were monitored using a laser particle counter (LPC). Participants recorded symptom scores at time points from baseline up to 24 h post-onset of allergen exposure. Participants returned to the research site for a 24-hour Follow-up visit. Allergic participants completed a cat exposure and Quality of Life questionnaire.

Results

Cat-allergic participants have distinct symptom profiles compared
to non-allergic participants

Forty-six (31 cat-allergic and 15 non-allergic) participants completed this study. Allergic participants had significantly larger (p < 0.0001) SPT wheals to cat hair than non-allergic controls. Twenty-five participants attended the first Session (mean Fel d 1 = 35.7 ng/m3), and 21 participants attended the second Session (mean Fel d 1 = 102.3 ng/m3).

The Evolution of IgE-Based Allergy Testing in Atopic Dermatitis: Where Do We Stand?

Braun C, Graham F, Fleischer DM et al.  J Allergy Clin Immunol Pract. 2025 May 12:S2213-2198(25)00437-4. doi: 10.1016/j.jaip.2025.05.013.

Abstract

Hypothetical mechanisms of IgE sensitization without clinical
allergic mast cell reactivity in patients with atopic dermatitis (AD).

The pathophysiology of atopic dermatitis (AD) involves cutaneous inflammation, predominantly mediated by innate immunity and T cells, in which IgE has a marginal role in most patients. Over previous decades, however, there has been an ongoing debate regarding the relevance of IgE-mediated allergy testing in patients with AD. Patients with AD have a defective skin barrier that facilitates a high inflammatory response to environmental antigens, placing them at greater risk for food allergies. Nevertheless, because these patients often produce high levels of IgE, the positive predictive value of skin prick tests and specific IgE measurements is low; such tests should be performed only when there is a concordant immediate hypersensitivity reaction (ie, urticaria or angioedema) rather than eczema.

The Predictive Value of Serum Total IgE for Antihistamine Treatment Outcomes in Chinese Patients with Chronic Spontaneous Urticaria

Li Y, Peng R, Xue J, Zhao Y. Acta Derm Venereol. 2025 Aug 3;105:adv43568. doi: 10.2340/actadv.v105.43568.

Abstract

 Comparison of clinical and laboratory characteristics
between responders and non-responders to
standard-dosed second-generation H1-antihistamines
(sgAHs) in patients with chronic spontaneous
urticaria (CSU)

Chronic spontaneous urticaria is a common skin disorder with variable treatment responses. Second-generation H1-antihistamines are the first-line treatment for chronic spontaneous urticaria, yet many patients fail to respond to licensed doses. Predictors of treatment response to second-generation H1-antihistamines could help optimize disease management and minimize unnecessary healthcare costs. In this retrospective cohort study of 99 Chinese chronic spontaneous urticaria patients, higher log-transformed serum total IgE levels were significantly associated with poor response to standard-dose antihistamines (aOR = 2.09, 95% CI: 1.29–3.38, p = 0.003).

A mucosal vaccine prevents eosinophilic allergic airway inflammation by modulating immune responses to allergens in a murine model of airway disease

Sevilla-Ortega, C., Angelina, A., Martín-Cruz, L. et al.  Nat Commun 16, 7129 (2025). https://doi.org/10.1038/s41467-025-62632-x

Abstract

MV130 prophylactic treatment prevents allergic sensitization
and HDM-induced eosinophilic airway inflammation, conferring
protection up to 9 weeks after treatment discontinuation.

Allergic sensitization and viral infections are risk factors for asthma development and progression. Sublingual vaccination with MV130, a whole heat-inactivated polybacterial preparation, protects against viral infections, but its impact on allergic sensitization and asthma development remains unknown. Here we show MV130 prevents house dust mite (HDM)-induced local type 2 immune responses and associated eosinophilic airway inflammation, conferring protection up to 9 weeks after vaccination.

Urticaria Voices: Real-World Treatment Patterns and Outcomes in Chronic Spontaneous Urticaria.

Bernstein, J.A., Winders, T.A., McCarthy, J. et al.  Dermatol Ther (Heidelb) 15, 2201–2215 (2025). https://doi.org/10.1007/s13555-025-01461-8

Abstract

Introduction

Chronic spontaneous urticaria (CSU) is characterized by itchy wheals/hives and/or angioedema lasting longer than 6 weeks. Herein, we describe patients’ perspectives from the global Urticaria Voices study reporting treatment patterns, disease burden, treatment satisfaction, and expectations.

Methods

This global, cross-sectional online survey was conducted from February to September 2022 in patients with CSU. Eligible patients had a self-reported clinician-provided diagnosis of CSU. Data were analyzed descriptively and reported as percentages (n/N), means (standard deviation [SD]), or 95% confidence intervals.

Results

Patient-reported disease control with H1-antihistamines

Overall, 582 patients with CSU were included in this analysis (62% women; mean [SD] age: 42.0 [11.9] years). At the time of the survey, patients reported taking 2.9 (2.6) concomitant therapies; most patients (79%) were prescribed H1-antihistamines (H1-AH), of which 42% took first-generation H1-AH and 52% took second-generation H1-AH.

Perspectives in the Molecular Mechanisms Underlying Anaphylaxis

Esteban V, Skrabski F, Perales-Chorda C, Puente-Crespo Y, Muñoz-Cano R, Cardona V; Anaphylaxis Committee of the Spanish Society of Allergy and Immunology (SEAIC).                   J Investig Allergol Clin Immunol. 2025 Jul 29;35(4):251-266. doi: 10.18176/jiaci.1080.

Abstract

The complexity of anaphylaxis in terms of clinical features and etiology-pathogenesis makes it difficult to establish precise endotypes that correspond to specific phenotypes. Therefore, interest in unravelling the cellular and molecular mechanisms underlying anaphylactic reactions has grown.
A large group of anaphylactic reactions are characterized by the classical immunological mechanism of type I hypersensitivity, which leads to IgE-mediated activation of mast cells and basophils.

Hypersensitivity Reactions to Gadolinium-Based Contrast Agents: Update From an Allergist's Point of View

Losa F, Paoletti G, Costanzo G, et al.  Clin Transl Allergy. 2025;e70086. https://doi.org/10.1002/clt2.70086

ABSTRACT

Background

The increasing use of Magnetic Resonance Imaging (MRI) has led to a rise in the administration of gadolinium-based contrast agents (GBCAs), accompanied by a growing number of reported adverse events (AEs).

Objective

This review aims to provide an updated overview of hypersensitivity reactions (HSRs) to GBCAs, focusing on diagnostic and management strategies from an allergological perspective.

Cross-reactivity patterns in IgE- and T-cell-mediated hypersensitivity
reactions to gadolinium-based contrast agents (GBCAs).

Methods

We reviewed recent literature concerning the classification, clinical presentation, and pathophysiological mechanisms of HSRs to GBCAs. Particular attention was given to current recommendations for diagnosis, risk stratification, and prevention.

Exploring the impact of chronic urticaria profile as a key predictor of alexithymia: A cross-sectional study

Ojeda IC, Thomsen SF, Gimenez-Arnau AM et al. Clin Transl Allergy. 2025 Jul;15(7):e70075. doi: 10.1002/clt2.70075.

Abstract

Introduction

The relationship between chronic urticaria (CU) and alexithymia, a cognitive-affective impairment characterized by difficulty in identifying and expressing emotions, is complex and underexplored. This study aimed to identify predictors of alexithymia in CU patients by focusing on the impact of coexisting mental illnesses and antihistamine use.

Methods

An online survey was distributed to specialized allergy and dermatology centers from 2021 to 2022. The survey included the TAS-20, UAS-7, UCT, CU-Q2oL, and demographic information. Participants were 18–80 years old, diagnosed with CU, and had no prior diagnosis of alexithymia.